Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies2025 · 1 citations
2. 2All-in-one Hangzhou Protocol: killing four birds with one stone2024 · 2 citations
3. 3CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
4. 4A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous <scp>CD7</scp> chimeric antigen receptor T‐cell therapy2024 · 13 citations
5. 5Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation2024 · 4 citations